Cargando…
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Lung cancer currently stands out as both the most common and the most lethal type of cancer, the latter feature being partly explained by the fact that the majority of lung cancer patients already display advanced disease at the time of diagnosis. In recent years, the development of specific tyrosin...
Autores principales: | Bersani, Francesca, Morena, Deborah, Picca, Francesca, Morotti, Alessandro, Tabbò, Fabrizio, Bironzo, Paolo, Righi, Luisella, Taulli, Riccardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815341/ https://www.ncbi.nlm.nih.gov/pubmed/33489823 http://dx.doi.org/10.21037/tlcr-20-189 |
Ejemplares similares
-
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
por: Tabbò, Fabrizio, et al.
Publicado: (2020) -
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020) -
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
por: Passiglia, Francesco, et al.
Publicado: (2020) -
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020) -
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)